Copyright Reports & Markets. All rights reserved.

Global Gynecological Cancer Diagnostics Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Gynecological Cancer Diagnostics by Type
    • 1.3.1 Overview: Global Gynecological Cancer Diagnostics Market Size by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Global Gynecological Cancer Diagnostics Consumption Value Market Share by Type in 2024
    • 1.3.3 Genetic Counseling Test
    • 1.3.4 Cancer Risk Test
    • 1.3.5 Kits Test
  • 1.4 Global Gynecological Cancer Diagnostics Market by Application
    • 1.4.1 Overview: Global Gynecological Cancer Diagnostics Market Size by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Gestational Trophoblastic Disease Diagnostics
    • 1.4.3 Endometrial Cancer Diagnostics
    • 1.4.4 Peritoneal Cancer Diagnostics
    • 1.4.5 Cervical Cancer Diagnostics
    • 1.4.6 Ovarian Cancer Diagnostics
    • 1.4.7 Vaginal Cancer Diagnostics
    • 1.4.8 Uterine Cancer Diagnostics
    • 1.4.9 Vulvar Cancer Diagnostics
  • 1.5 Global Gynecological Cancer Diagnostics Market Size & Forecast
  • 1.6 Global Gynecological Cancer Diagnostics Market Size and Forecast by Region
    • 1.6.1 Global Gynecological Cancer Diagnostics Market Size by Region: 2020 VS 2024 VS 2031
    • 1.6.2 Global Gynecological Cancer Diagnostics Market Size by Region, (2020-2031)
    • 1.6.3 North America Gynecological Cancer Diagnostics Market Size and Prospect (2020-2031)
    • 1.6.4 Europe Gynecological Cancer Diagnostics Market Size and Prospect (2020-2031)
    • 1.6.5 Asia-Pacific Gynecological Cancer Diagnostics Market Size and Prospect (2020-2031)
    • 1.6.6 South America Gynecological Cancer Diagnostics Market Size and Prospect (2020-2031)
    • 1.6.7 Middle East & Africa Gynecological Cancer Diagnostics Market Size and Prospect (2020-2031)

2 Company Profiles

  • 2.1 UT Southwestern
    • 2.1.1 UT Southwestern Details
    • 2.1.2 UT Southwestern Major Business
    • 2.1.3 UT Southwestern Gynecological Cancer Diagnostics Product and Solutions
    • 2.1.4 UT Southwestern Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 UT Southwestern Recent Developments and Future Plans
  • 2.2 Abramson Cancer Center
    • 2.2.1 Abramson Cancer Center Details
    • 2.2.2 Abramson Cancer Center Major Business
    • 2.2.3 Abramson Cancer Center Gynecological Cancer Diagnostics Product and Solutions
    • 2.2.4 Abramson Cancer Center Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Abramson Cancer Center Recent Developments and Future Plans
  • 2.3 Northwestern Medicine
    • 2.3.1 Northwestern Medicine Details
    • 2.3.2 Northwestern Medicine Major Business
    • 2.3.3 Northwestern Medicine Gynecological Cancer Diagnostics Product and Solutions
    • 2.3.4 Northwestern Medicine Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 Northwestern Medicine Recent Developments and Future Plans
  • 2.4 Sysmex Europe SE
    • 2.4.1 Sysmex Europe SE Details
    • 2.4.2 Sysmex Europe SE Major Business
    • 2.4.3 Sysmex Europe SE Gynecological Cancer Diagnostics Product and Solutions
    • 2.4.4 Sysmex Europe SE Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Sysmex Europe SE Recent Developments and Future Plans
  • 2.5 Fujirebio
    • 2.5.1 Fujirebio Details
    • 2.5.2 Fujirebio Major Business
    • 2.5.3 Fujirebio Gynecological Cancer Diagnostics Product and Solutions
    • 2.5.4 Fujirebio Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Fujirebio Recent Developments and Future Plans
  • 2.6 Premier Health
    • 2.6.1 Premier Health Details
    • 2.6.2 Premier Health Major Business
    • 2.6.3 Premier Health Gynecological Cancer Diagnostics Product and Solutions
    • 2.6.4 Premier Health Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 Premier Health Recent Developments and Future Plans
  • 2.7 Agilent Technologies, Inc
    • 2.7.1 Agilent Technologies, Inc Details
    • 2.7.2 Agilent Technologies, Inc Major Business
    • 2.7.3 Agilent Technologies, Inc Gynecological Cancer Diagnostics Product and Solutions
    • 2.7.4 Agilent Technologies, Inc Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 Agilent Technologies, Inc Recent Developments and Future Plans
  • 2.8 ARUP Laboratories
    • 2.8.1 ARUP Laboratories Details
    • 2.8.2 ARUP Laboratories Major Business
    • 2.8.3 ARUP Laboratories Gynecological Cancer Diagnostics Product and Solutions
    • 2.8.4 ARUP Laboratories Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 ARUP Laboratories Recent Developments and Future Plans
  • 2.9 CENTOGENE
    • 2.9.1 CENTOGENE Details
    • 2.9.2 CENTOGENE Major Business
    • 2.9.3 CENTOGENE Gynecological Cancer Diagnostics Product and Solutions
    • 2.9.4 CENTOGENE Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.9.5 CENTOGENE Recent Developments and Future Plans
  • 2.10 F. Hoffmann-La Roche Ltd
    • 2.10.1 F. Hoffmann-La Roche Ltd Details
    • 2.10.2 F. Hoffmann-La Roche Ltd Major Business
    • 2.10.3 F. Hoffmann-La Roche Ltd Gynecological Cancer Diagnostics Product and Solutions
    • 2.10.4 F. Hoffmann-La Roche Ltd Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.10.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
  • 2.11 Fulgent Genetics, Inc
    • 2.11.1 Fulgent Genetics, Inc Details
    • 2.11.2 Fulgent Genetics, Inc Major Business
    • 2.11.3 Fulgent Genetics, Inc Gynecological Cancer Diagnostics Product and Solutions
    • 2.11.4 Fulgent Genetics, Inc Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.11.5 Fulgent Genetics, Inc Recent Developments and Future Plans
  • 2.12 Invitae Corporation
    • 2.12.1 Invitae Corporation Details
    • 2.12.2 Invitae Corporation Major Business
    • 2.12.3 Invitae Corporation Gynecological Cancer Diagnostics Product and Solutions
    • 2.12.4 Invitae Corporation Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.12.5 Invitae Corporation Recent Developments and Future Plans
  • 2.13 Myriad Genetics, Inc
    • 2.13.1 Myriad Genetics, Inc Details
    • 2.13.2 Myriad Genetics, Inc Major Business
    • 2.13.3 Myriad Genetics, Inc Gynecological Cancer Diagnostics Product and Solutions
    • 2.13.4 Myriad Genetics, Inc Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.13.5 Myriad Genetics, Inc Recent Developments and Future Plans
  • 2.14 BGI Group
    • 2.14.1 BGI Group Details
    • 2.14.2 BGI Group Major Business
    • 2.14.3 BGI Group Gynecological Cancer Diagnostics Product and Solutions
    • 2.14.4 BGI Group Gynecological Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.14.5 BGI Group Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Gynecological Cancer Diagnostics Revenue and Share by Players (2020-2025)
  • 3.2 Market Share Analysis (2024)
    • 3.2.1 Market Share of Gynecological Cancer Diagnostics by Company Revenue
    • 3.2.2 Top 3 Gynecological Cancer Diagnostics Players Market Share in 2024
    • 3.2.3 Top 6 Gynecological Cancer Diagnostics Players Market Share in 2024
  • 3.3 Gynecological Cancer Diagnostics Market: Overall Company Footprint Analysis
    • 3.3.1 Gynecological Cancer Diagnostics Market: Region Footprint
    • 3.3.2 Gynecological Cancer Diagnostics Market: Company Product Type Footprint
    • 3.3.3 Gynecological Cancer Diagnostics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Gynecological Cancer Diagnostics Consumption Value and Market Share by Type (2020-2025)
  • 4.2 Global Gynecological Cancer Diagnostics Market Forecast by Type (2026-2031)

5 Market Size Segment by Application

  • 5.1 Global Gynecological Cancer Diagnostics Consumption Value Market Share by Application (2020-2025)
  • 5.2 Global Gynecological Cancer Diagnostics Market Forecast by Application (2026-2031)

6 North America

  • 6.1 North America Gynecological Cancer Diagnostics Consumption Value by Type (2020-2031)
  • 6.2 North America Gynecological Cancer Diagnostics Market Size by Application (2020-2031)
  • 6.3 North America Gynecological Cancer Diagnostics Market Size by Country
    • 6.3.1 North America Gynecological Cancer Diagnostics Consumption Value by Country (2020-2031)
    • 6.3.2 United States Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 6.3.3 Canada Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 6.3.4 Mexico Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)

7 Europe

  • 7.1 Europe Gynecological Cancer Diagnostics Consumption Value by Type (2020-2031)
  • 7.2 Europe Gynecological Cancer Diagnostics Consumption Value by Application (2020-2031)
  • 7.3 Europe Gynecological Cancer Diagnostics Market Size by Country
    • 7.3.1 Europe Gynecological Cancer Diagnostics Consumption Value by Country (2020-2031)
    • 7.3.2 Germany Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 7.3.3 France Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 7.3.4 United Kingdom Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 7.3.5 Russia Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 7.3.6 Italy Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)

8 Asia-Pacific

  • 8.1 Asia-Pacific Gynecological Cancer Diagnostics Consumption Value by Type (2020-2031)
  • 8.2 Asia-Pacific Gynecological Cancer Diagnostics Consumption Value by Application (2020-2031)
  • 8.3 Asia-Pacific Gynecological Cancer Diagnostics Market Size by Region
    • 8.3.1 Asia-Pacific Gynecological Cancer Diagnostics Consumption Value by Region (2020-2031)
    • 8.3.2 China Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 8.3.3 Japan Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 8.3.4 South Korea Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 8.3.5 India Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 8.3.6 Southeast Asia Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 8.3.7 Australia Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)

9 South America

  • 9.1 South America Gynecological Cancer Diagnostics Consumption Value by Type (2020-2031)
  • 9.2 South America Gynecological Cancer Diagnostics Consumption Value by Application (2020-2031)
  • 9.3 South America Gynecological Cancer Diagnostics Market Size by Country
    • 9.3.1 South America Gynecological Cancer Diagnostics Consumption Value by Country (2020-2031)
    • 9.3.2 Brazil Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 9.3.3 Argentina Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)

10 Middle East & Africa

  • 10.1 Middle East & Africa Gynecological Cancer Diagnostics Consumption Value by Type (2020-2031)
  • 10.2 Middle East & Africa Gynecological Cancer Diagnostics Consumption Value by Application (2020-2031)
  • 10.3 Middle East & Africa Gynecological Cancer Diagnostics Market Size by Country
    • 10.3.1 Middle East & Africa Gynecological Cancer Diagnostics Consumption Value by Country (2020-2031)
    • 10.3.2 Turkey Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 10.3.3 Saudi Arabia Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 10.3.4 UAE Gynecological Cancer Diagnostics Market Size and Forecast (2020-2031)

11 Market Dynamics

  • 11.1 Gynecological Cancer Diagnostics Market Drivers
  • 11.2 Gynecological Cancer Diagnostics Market Restraints
  • 11.3 Gynecological Cancer Diagnostics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Gynecological Cancer Diagnostics Industry Chain
  • 12.2 Gynecological Cancer Diagnostics Upstream Analysis
  • 12.3 Gynecological Cancer Diagnostics Midstream Analysis
  • 12.4 Gynecological Cancer Diagnostics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Gynecological Cancer Diagnostics market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Gynecological Cancer Diagnostics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Gynecological Cancer Diagnostics market size and forecasts, in consumption value ($ Million), 2020-2031
    Global Gynecological Cancer Diagnostics market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
    Global Gynecological Cancer Diagnostics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
    Global Gynecological Cancer Diagnostics market shares of main players, in revenue ($ Million), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Gynecological Cancer Diagnostics
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Gynecological Cancer Diagnostics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include UT Southwestern, Abramson Cancer Center, Northwestern Medicine, Sysmex Europe SE, Fujirebio, Premier Health, Agilent Technologies, Inc, ARUP Laboratories, CENTOGENE, F. Hoffmann-La Roche Ltd, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Gynecological Cancer Diagnostics market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Genetic Counseling Test
    Cancer Risk Test
    Kits Test
    Market segment by Application
    Gestational Trophoblastic Disease Diagnostics
    Endometrial Cancer Diagnostics
    Peritoneal Cancer Diagnostics
    Cervical Cancer Diagnostics
    Ovarian Cancer Diagnostics
    Vaginal Cancer Diagnostics
    Uterine Cancer Diagnostics
    Vulvar Cancer Diagnostics
    Market segment by players, this report covers
    UT Southwestern
    Abramson Cancer Center
    Northwestern Medicine
    Sysmex Europe SE
    Fujirebio
    Premier Health
    Agilent Technologies, Inc
    ARUP Laboratories
    CENTOGENE
    F. Hoffmann-La Roche Ltd
    Fulgent Genetics, Inc
    Invitae Corporation
    Myriad Genetics, Inc
    BGI Group
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Gynecological Cancer Diagnostics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Gynecological Cancer Diagnostics, with revenue, gross margin, and global market share of Gynecological Cancer Diagnostics from 2020 to 2025.
    Chapter 3, the Gynecological Cancer Diagnostics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Gynecological Cancer Diagnostics market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Gynecological Cancer Diagnostics.
    Chapter 13, to describe Gynecological Cancer Diagnostics research findings and conclusion.

    Buy now